Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-15

Study Completion Date

2024-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

NCT06527846

Kidney Disease, Chronic

ACTIVE_NOT_RECRUITING

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

NCT06287073

Kidney Disease, Chronic

COMPLETED

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

NCT01001962

Hypertension Type II Diabetes

UNKNOWN PHASE4

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

NCT06337409

Healthy Volunteer

NOT_YET_RECRUITING PHASE1

Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients

NCT05335629

Myocardial Infarction Diabetes Mellitus, Type 2 Myocardial Remodeling, Ventricular

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

JARDIANCE®

Patients in Japan with chronic heart failure who were prescribed JARDIANCE® tablets and who were never treated with Empagliflozin before enrolment. Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS). Patients were observed for up to 52 weeks after start of the treatment or until discontinuation of administration.

JARDIANCE®

Intervention Type DRUG

Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JARDIANCE®

Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

empagliflozin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan
* Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment